GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » Accounts Receivable

Eupraxia Pharmaceuticals (TSX:EPRX) Accounts Receivable : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Eupraxia Pharmaceuticals's accounts receivables for the quarter that ended in Mar. 2024 was C$0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Eupraxia Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was C$0.71.


Eupraxia Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Accounts Receivable Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial - - - - -

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Eupraxia Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Eupraxia Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Eupraxia Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Eupraxia Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Eupraxia Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(48.605+0.75 * 0+0.5 * 0-25.081
-0--1.946)/35.6226
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Eupraxia Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Traded in Other Exchanges
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Executives
James Allen Helliwell Director